Moderna, Inc. (MRNA) Discusses Advancements in mRNA Technology, Clinical Modalities, and Future Horizons in Science June 25, 2026 9:00 AM EDT
Company Participants
Stéphane Bancel – CEO & Director
David Berman – Chief Development Officer
Rose Loughlin – Executive Vice President of Research
Kristine McKinney – Vice President & Head of Cancer Vaccines Research
David Church
Sarah Keidel
Lin Guey
Sumana Chandramouli
David Huss
Lavina Talukdar – Senior VP & Head of Investor Relations
Conference Call Participants
Edward Tenthoff – Piper Sandler & Co., Research Division
Lin Tsai – Jefferies LLC, Research Division
Mark Allen
Gregory Wiessner – TD Cowen, Research Division
Matthew Hagood – UBS Investment Bank, Research Division
Alexandria Hammond
Myles Minter – William Blair & Company L.L.C., Research Division
Shelby Hill – RBC Capital Markets, Research Division
Chun Yu – Morgan Stanley, Research Division
Lili Nsongo – Leerink Partners LLC, Research Division
Presentation
Stéphane Bancel
CEO & Director
Good morning, and good afternoon for those of you that are following us from overseas. Thank you so much for joining us today. On behalf of my colleagues and I, welcome to Moderna’s Science Day 2026. Before I start, let me remind you that we’ll be making forward-looking statements. You can find those online at your discretion. Moderna’s mission is to deliver the greatest possible impact to people through mRNA medicine.
And since the beginning, we built an mRNA platform based on 3 key pillars of science: mRNA science, which is the mRNA molecule itself, delivery system, how we get the mRNA molecule into cells and very importantly, also manufacturing processes where there’s a lot of know-how that we developed over the years. But because mRNA is an information molecule, what is very exciting about this platform is we can create modalities, families of medicine that use exactly the same technology features so that we can replicate very quickly.
As you can see on the pictogram
